Literature DB >> 26984631

Increased 5-hydroxymethylcytosine in CD4(+) T cells in systemic lupus erythematosus.

Ming Zhao1, Jing Wang1, Wei Liao1, Duo Li1, Mengying Li1, Haijing Wu1, Yiqun Zhang1, M Eric Gershwin2, Qianjin Lu3.   

Abstract

One of the major disappointments in autoimmunity has been the relative lack of informative data when genomewide associations (GWAS) have been applied to patients with systemic lupus erythematosus (SLE). Indeed, there is increasing evidence that SLE is characterized by widespread epigenetic changes. 5-Hydroxymethylcytosine (5-hmC) is a newly discovered modified form of cytosine suspected to be an important epigenetic modification in embryonic development, cell differentiation and cancer. DNA methylation dynamics have already been implicated in the pathogenesis of SLE, while little is known about hydroxymethylation in this process. Here, we show an increased 5-hmC level in genomic DNA in CD4(+) T cells of patients with SLE compared with healthy controls, accompanied by the up-regulated expression of the Ten-eleven translocation TET2 and TET3, which can enzymatically convert 5-methylcytosine (5-mC) to 5-hmC. Moreover, we present the differential patterns of DNA hydroxymethylation in genome-wide promoter regions in SLE CD4(+) T cells compared with healthy controls. We identified 2748 genes with increased 5-hmC levels in promoter regions in SLE CD4(+) T cells, which were enriched in critical pathways, including neurotrophin signaling, WNT signaling, MAPK signaling, calcium signaling and the mTOR signaling pathway. Through a combined analysis of differential DNA hydroxymethylation profile and gene expression profile in SLE CD4(+) T cells, we found 131 genes with the increased 5-hmC in promoter regions and up-regulated expression in SLE CD4(+) T cells compared with healthy controls, including selected immune-related genes, i.e. SOCS1, NR2F6 and IL15RA, which were also confirmed by ChIP-qPCR. Furthermore, we demonstrate that CTCF, as a transcription factor, can mediate DNA hydroxymethylation and contribute to overexpression of SOCS1 in CD4(+) T cells through binding to the promoter region of SOCS1. Taken together, our study reveals a critical differential 5-hmC in the genome-wide promoter regions of SLE CD4(+) T cells and provides a novel mechanism that suggests that DNA hydroxymethylation contributes to the aberrant regulation of genes transcription in the pathogenesis of SLE.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD4(+) T cells; CTCF; Epigenetics; Hydroxymethylation; Methylation; SOCS1; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 26984631     DOI: 10.1016/j.jaut.2016.03.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  32 in total

Review 1.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

Review 2.  New insights into the immunopathogenesis of systemic lupus erythematosus.

Authors:  George C Tsokos; Mindy S Lo; Patricia Costa Reis; Kathleen E Sullivan
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

3.  17β-Estradiol and 17α-Ethinyl Estradiol Exhibit Immunologic and Epigenetic Regulatory Effects in NZB/WF1 Female Mice.

Authors:  Rujuan Dai; Michael R Edwards; Bettina Heid; S Ansar Ahmed
Journal:  Endocrinology       Date:  2019-01-01       Impact factor: 4.736

Review 4.  DNA methylation in systemic lupus erythematosus.

Authors:  Christian M Hedrich; Katrin Mäbert; Thomas Rauen; George C Tsokos
Journal:  Epigenomics       Date:  2016-11-25       Impact factor: 4.778

Review 5.  Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.

Authors:  Zachary Oaks; Thomas Winans; Nick Huang; Katalin Banki; Andras Perl
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

Review 6.  Autoimmunity in 2016.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 7.  Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous.

Authors:  Arron Munggela Foma; Saeed Aslani; Jafar Karami; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Inflamm Res       Date:  2017-07-24       Impact factor: 4.575

8.  PPP2R2B hypermethylation causes acquired apoptosis deficiency in systemic autoimmune diseases.

Authors:  Iris K Madera-Salcedo; Beatriz E Sánchez-Hernández; Yevgeniya Svyryd; Marcela Esquivel-Velázquez; Noé Rodríguez-Rodríguez; María Isabel Trejo-Zambrano; H Benjamín García-González; Gabriela Hernández-Molina; Osvaldo M Mutchinick; Jorge Alcocer-Varela; Florencia Rosetti; José C Crispín
Journal:  JCI Insight       Date:  2019-07-23

Review 9.  DNA methylation alterations in the pathogenesis of lupus.

Authors:  S H Chen; Q L Lv; L Hu; M J Peng; G H Wang; B Sun
Journal:  Clin Exp Immunol       Date:  2016-11-01       Impact factor: 4.330

Review 10.  Epigenetics of inflammatory arthritis.

Authors:  Deepa Hammaker; Gary S Firestein
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.